Fennec Pharmaceuticals Inc.
NASDAQ: FENC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeffrey S. Hackman
- Employees
- 32
- Headquarters
- Research Triangle Park, United States
- IPO year
- 2017
- Market cap
- $297.2M
- Website
- https://www.fennecpharma.com
Loading FENC…
Loading profile data…Frequently asked questions about FENC
What does Fennec Pharmaceuticals Inc. (FENC) do?
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which...
Where does FENC trade?
Fennec Pharmaceuticals Inc. (FENC) trades on the NASDAQ Capital Market.
What sector is FENC in?
Fennec Pharmaceuticals Inc. (FENC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Fennec Pharmaceuticals Inc.?
Jeffrey S. Hackman is the chief executive officer of Fennec Pharmaceuticals Inc. (FENC).
Where is Fennec Pharmaceuticals Inc. headquartered?
Fennec Pharmaceuticals Inc. is headquartered in United States.
Does FENC pay a dividend?
Fennec Pharmaceuticals Inc. (FENC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FENC go public?
Fennec Pharmaceuticals Inc. (FENC) completed its initial public offering in 2017.